Roy Lester Freeman - Jan 21, 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Milton H. Werner, attorney-in-fact
Stock symbol
IKT
Transactions as of
Jan 21, 2025
Transactions value $
$0
Form type
4
Date filed
1/22/2025, 04:05 PM
Previous filing
Jan 7, 2025
Next filing
Feb 19, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -21.9K -100% $0.00 0 Jan 21, 2025 Common Stock 21.9K $33.43 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +21.9K $0.00 21.9K Jan 21, 2025 Common Stock 21.9K $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -1.14K -100% $0.00 0 Jan 21, 2025 Common Stock 1.14K $60.00 Direct F1, F2, F3, F4
transaction IKT Stock Option (Right to Buy) Award $0 +1.14K $0.00 1.14K Jan 21, 2025 Common Stock 1.14K $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -3.78K -100% $0.00 0 Jan 21, 2025 Common Stock 3.78K $17.52 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +3.78K $0.00 3.78K Jan 21, 2025 Common Stock 3.78K $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -6.67K -100% $0.00 0 Jan 21, 2025 Common Stock 6.67K $4.86 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +6.67K $0.00 6.67K Jan 21, 2025 Common Stock 6.67K $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -6.67K -100% $0.00 0 Jan 21, 2025 Common Stock 6.67K $3.61 Direct F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +6.67K $0.00 6.67K Jan 21, 2025 Common Stock 6.67K $1.26 Direct F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -30K -100% $0.00 0 Jan 21, 2025 Common Stock 30K $1.54 Direct F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +30K $0.00 30K Jan 21, 2025 Common Stock 30K $1.26 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
F2 The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F3 This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
F4 The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030.